# South America Geographic Atrophy (GA) Market > South America Geographic Atrophy GA Market Research Report By Age Group (Above 60 Years, Above 75 Years), By Diagnosis (Fundus Autofluorescence, Optical Coherence Tomography Angiography, Multifocal Electroretinography), By Therapeutic Agents Clinical Phase (Late-Stage, Phase II, Phase I, Pre-Clinical Stage, Discovery Candidates) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.28% - **2024:** $ 1,200 Million - **2025:** $ 1,287.36 Million - **2035:** $ 2,600 Million - **Key Players:** Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Alcon (CH), Apellis Pharmaceuticals (US), Genentech (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE) **Report ID:** MRFR/HC/49913-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-geographic-atrophy-ga-market-51671 --- ## Market Summary ## **South America Geographic Atrophy GA Market Overview** As per MRFR analysis, the South America Geographic Atrophy GA Market Size was estimated at 1.08 (USD Billion) in 2024.The South America Geographic Atrophy GA Market Industry is expected to grow from 1.11(USD Billion) in 2025 to 2.24 (USD Billion) by 2035. The South America Geographic Atrophy GA Market CAGR (growth rate) is expected to be around 6.579% during the forecast period (2025 - 2035). ### **Key South America Geographic Atrophy GA Market Trends Highlighted** In South America, the Geographic Atrophy (GA) market is experiencing significant developments driven by an aging population and increasing awareness of age-related macular degeneration. With life expectancy rising in countries like Brazil and Argentina, the prevalence of GA is also growing, urging healthcare providers to prioritize research and treatment options. The demand for innovative therapies is further catalyzed by advancements in technology and increased focus on ophthalmology research, aiming to provide better diagnostic tools and treatment solutions. times have observed a surge in collaborations among pharmaceutical firms and research institutions in South America. This trend is notable in countries like Chile and Colombia, where clinical trials are gaining pace, allowing for a quicker understanding of GA treatment efficacy. Telemedicine and digital health solutions are finding a foothold in the South American healthcare landscape, offering remote access to specialists and facilitating early diagnosis and intervention for at-risk patients. Despite challenges, there are opportunities to be explored in the South American GA market. The incorporation of artificial intelligence in diagnosing eye diseases represents a promising frontier, enhancing precision and patient outcomes. Moreover, new policies aimed at improving healthcare access, particularly in rural areas, could facilitate better treatment for GA patients.Overall, with the combination of rising public health initiatives and technological innovations, the South American Geographic Atrophy market shows substantial potential for growth and improvement in patient care. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South America Geographic Atrophy GA Market Drivers** Growing Aging Population Driving Increased Demand The South America Geographic Atrophy GA Market Industry is expected to see accelerated growth due to an increasing aging population. According to data from the United Nations, the population aged 60 years and older in South America is projected to increase by approximately 25% in the next decade. This demographic trend is particularly pronounced in countries like Brazil and Argentina, which host significant portions of the elderly . The World Health Organization has highlighted that age-related eye diseases, including geographic atrophy, are becoming more prevalent with the aging population. As healthcare systems adapt, the demand for specialized treatments and interventions in geographic atrophy will further increase, especially with established organizations like the Brazilian Society of Ophthalmology focusing on awareness and treatment of age-related macular degeneration. This driver reaffirms the necessity for investments in the South America Geographic Atrophy GA Market, as stakeholders work to address the growing needs of this demographic. Advancements in Research and Development Significant advancements in Research and Development (R&D) related to geographic atrophy treatments are fostering growth in the South America Geographic Atrophy GA Market Industry. The Latin American Council of Ophthalmology, along with other medical institutions, is prioritizing innovative solutions for managing geographic atrophy, leading to numerous clinical trials in the region. Data from the National Agency for Health Surveillance in Brazil indicates that there has been a 30% increase in research initiatives related to eye health in the past five years.This increase is critical as new therapies continue to emerge, paving the way for better patient outcomes and consequently increasing market potential. The involvement of major pharmaceutical companies in local partnerships also signals a commitment to addressing geographic atrophy issues, ensuring that research flows into practical treatment options. Increasing Awareness and Diagnosis of Eye Diseases There is a growing awareness about eye diseases, particularly geographic atrophy, in South America, which is significantly affecting the South America Geographic Atrophy GA Market Industry. A recent campaign organized by the Argentine Society of Ophthalmology has highlighted the importance of early detection and treatment for diseases linked to age-related vision decline. Their findings showed that roughly 40% of individuals aged above 50 are unaware of the risk factors associated with geographic atrophy.With the deployment of community outreach programs and educational initiatives, there is greater public awareness, which is likely to increase the number of patients seeking diagnosis and treatment, and, in turn, foster market growth. Efforts by health care providers in collaboration with non-governmental organizations help disseminate information, which aids in the construction of this favorable outlook. ## **South America Geographic Atrophy GA Market Segment Insights** ### **Geographic Atrophy GA Market Age Group Insights** The Age Group segmentation within the South America Geographic Atrophy GA Market reveals critical insights into the demographic trends shaping this sector. The population aged above 60 years is steadily increasing in South America, primarily due to longer life expectancies and improved healthcare systems, particularly in countries such as Brazil, Argentina, and Chile. This age group is extremely significant, as they tend to exhibit higher rates of geographic atrophy, making them a primary focus for the industry. As the population continues to age, there is an escalating demand for medical treatments aimed at mitigating the effects of age-related vision loss, highlighting the need for innovative therapies and supportive measures. In the Age Group of Above 75 years, the significance further amplifies due to the heightened prevalence of age-related conditions, including macular degeneration, which directly impacts vision quality. This demographic represents a vital part of the South America Geographic Atrophy GA Market as they typically require more intensive medical management and care options. Healthcare policies in South America are increasingly addressing the requirements for this elderly population, thus presenting valuable opportunities for stakeholders in the market aiming to cater to their needs. The growing awareness of geographic atrophy and its implications among healthcare providers and patients alike is also contributing to the market's expansion. Moreover, advancements in research and development are yielding promising outcomes, fostering a collaborative effort between various entities to improve treatment strategies and enhance patient outcomes. Overall, the Age Group segmentation indicates a clear focus on older adults as a critical market segment, emphasizing a collective responsibility towards developing effective healthcare solutions for the elderly population facing geographic atrophy and related issues in South America. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Geographic Atrophy GA Market Diagnosis Insights** The Diagnosis segment of the South America Geographic Atrophy GA Market plays a crucial role in the effective identification and assessment of geographic atrophy, a leading cause of vision loss. With a market poised for significant growth, the focus on advanced diagnostic technologies is becoming essential. Fundus Autofluorescence is critical as it provides detailed imaging of retinal tissues, enabling early detection of changes, which is vital for timely intervention. Similarly, Optical Coherence Tomography Angiography offers non-invasive imaging that enhances the visualization of retinal vascular structure, thus offering invaluable insights for clinical decision-making. Multifocal Electroretinography complements these techniques by assessing retinal function across various regions, providing a comprehensive evaluation that supports more tailored treatment strategies. As the South American population ages, increased prevalence of age-related macular degeneration necessitates the widespread adoption of these advanced diagnostic tools. The combination of these techniques represents a holistic approach to managing geographic atrophy, presenting opportunities for healthcare providers to enhance patient outcomes in this region.The South America Geographic Atrophy GA Market is characterized by a growing demand for innovative diagnostic solutions that are essential for combating this debilitating condition effectively. ### **Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Insights** The Therapeutic Agents Clinical Phase segment within the South America Geographic Atrophy GA Market is critical to enhancing treatment options and improving patient outcomes. This segment comprises various stages of drug development, including Late-Stage, Phase II, Phase I, Pre-Clinical Stage, and Discovery Candidates. Late-Stage therapies typically draw significant attention as they are closest to entering the market, holding promise for effective interventions. Meanwhile, Phase II trials focus on expanding understanding of treatment efficacy and safety, becoming essential for subsequent regulatory approvals. Phase I trials initiate safety testing in a small group of individuals, laying the foundation for further development. The Pre-Clinical Stage is vital in identifying potential therapeutic candidates before human trials, while Discovery Candidates represent innovative approaches to treatment that could reshape management of Geographic Atrophy. The South America region, with its aging population and rising prevalence of eye-related diseases, presents substantial opportunities for growth in these clinical phases, fueled by a combination of academic research, emerging biotech companies, and increasing investment in Research and Development.These dynamics collectively reflect the critical importance of the Therapeutic Agents Clinical Phase segment, positioning it as a key driver of progress in the management of Geographic Atrophy in South America. ### **Geographic Atrophy GA Market Regional Insights** The South America Geographic Atrophy GA Market is characterized by diverse regional dynamics that significantly contribute to market growth and segmentation. Brazil stands out as a significant player in this market due to its large population and high incidence of age-related macular degeneration, which drives demand for treatment options. Mexico also plays a crucial role with its expanding healthcare infrastructure and rising awareness about vision health, making it a growing market for Geographic Atrophy solutions. Argentina, with its increasing healthcare investment, is seeing enhanced access to advanced treatment methods, thus contributing to the overall market expansion.The Rest of South America is noteworthy, as it encompasses various countries that are gradually increasing health expenditures and adopting innovative therapies.  The combination of an aging population, increasing prevalence of chronic eye diseases, and advancements in medical technology are key growth driver across these regions. Furthermore, opportunities arise from the growing collaboration among healthcare providers and pharmaceutical companies to enhance treatment accessibility and affordability in the South America Geographic Atrophy GA Market.Understanding these regional characteristics is essential for stakeholders looking to optimize their strategies and meet the unique needs of the South American population. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South America Geographic Atrophy GA Market Key Players and Competitive Insights** The South America Geographic Atrophy GA Market is characterized by a burgeoning landscape driven by an increase in the aging population and a heightened prevalence of retinal diseases, particularly age-related macular degeneration. This market is witnessing intensified competition as various players strive to establish a foothold through innovative treatment options, advanced technologies, and strategic collaborations. The competitive dynamics are shaped by several factors including regulatory harmonization, shifting healthcare policies, and growing awareness among patients and healthcare providers about the significance of early diagnosis and intervention in managing Geographic Atrophy.  Companies are innovating their product pipelines to address unmet medical needs while also focusing on improving patient outcomes, thereby making this region a significant area for investment and growth in the ophthalmological sector.Carl Zeiss AG has significantly established its presence in the South American Geographic Atrophy GA Market through its advanced imaging solutions and diagnostic tools tailored for ophthalmology. The company's strengths lie in its robust R&D capabilities, allowing continuous innovation in visualization and precision measurement technologies that aid in the early detection of retinal conditions, including Geographic Atrophy. Its extensive distribution network in South America fosters a strong market presence, and partnerships with healthcare institutions enhance its credibility and reach.  The company's commitment to training and education for local healthcare practitioners further strengthens its position in the market, enabling better patient management for those suffering from sight-threatening conditions.Eyegate Pharmaceuticals is also a key player in the South American Geographic Atrophy GA Market, particularly known for its novel drug delivery systems and innovative therapies aimed at treating retinal diseases. The company focuses on developing biopharmaceutical products that allow for less invasive treatment options, thereby addressing a critical gap in the current treatment landscape.  Eyegate's strengths lie in its proprietary technologies that promise to enhance drug absorption and efficacy in the ophthalmic domain. The company has been pursuing strategic partnerships and collaborations within South America to expand its market reach and drive the commercial success of its key products. Eyegate's commitment to innovation is underscored by its active engagement in clinical trials and research initiatives designed to bolster its therapeutic offerings, ultimately enhancing patient outcomes in the region. **Key Companies in the South America Geographic Atrophy GA Market Include** ## **South America Geographic Atrophy GA Market Industry Developments** In the South America Geographic Atrophy (GA) Market, recent developments indicate a notable increase in Research and Development investments focusing on therapeutic options and diagnostic tools targeted at retinal diseases. Companies such as Novartis and Bayer are making strides with innovative treatment approaches, while Alcon has expanded its product offering in the region to cater to the growing demand for ophthalmic solutions. In September 2023, EyeGate Pharmaceuticals announced an agreement with a South American distributor to enhance the availability of its GA treatments. Additionally, Kowa Company reported improved market penetration through partnerships with local health authorities in Brazil. Notably, in August 2023, Roche expanded its collaboration with Astellas Pharma, aiming to accelerate the development of new therapies for macular degeneration, thus strengthening their presence in the South American market. The valuation of the Geographic Atrophy market is expected to rise due to increasing patient awareness and government initiatives to support eye health, particularly in Argentina and Chile. Over the past couple of years, significant efforts to increase accessibility to treatments have been observed, contributing positively to the evolving landscape of the Geographic Atrophy market in South America. ## **South America Geographic Atrophy GA Market Segmentation Insights** ### **Geographic Atrophy GA Market Age Group****Outlook** ### **Geographic Atrophy GA Market Diagnosis****Outlook** ### **Geographic Atrophy GA Market Therapeutic Agents Clinical Phase****Outlook** ### **Geographic Atrophy GA Market Regional****Outlook** ## Market Drivers ### Increasing Aging Population The demographic shift towards an older population in South America is a crucial driver for the geographic atrophy-ga market. As individuals age, the risk of developing age-related eye diseases, including geographic atrophy, escalates. Current estimates suggest that by 2030, approximately 20% of the South American population will be over 60 years old. This growing segment is likely to increase the demand for diagnostic and therapeutic options in the geographic atrophy-ga market. Furthermore, healthcare systems may need to adapt to accommodate the rising prevalence of this condition, potentially leading to increased funding and resources allocated to eye health initiatives. The aging population's impact on healthcare infrastructure could also stimulate innovation in treatment modalities, thereby enhancing the overall market landscape. ### Rising Healthcare Expenditure Healthcare expenditure in South America has been on an upward trajectory, which appears to positively influence the geographic atrophy-ga market. Increased spending on healthcare services, projected to reach $1 trillion by 2025, allows for better access to advanced diagnostic tools and treatment options for geographic atrophy. This financial commitment from both public and private sectors may facilitate the introduction of innovative therapies and technologies, thereby improving patient outcomes. Additionally, as healthcare budgets expand, there is a potential for increased awareness and education regarding geographic atrophy, leading to earlier diagnosis and intervention. This trend could ultimately drive market growth as more patients seek treatment for this debilitating condition. ### Technological Advancements in Diagnostics Technological innovations in diagnostic tools are significantly shaping the geographic atrophy-ga market in South America. Enhanced imaging techniques, such as optical coherence tomography (OCT), are becoming more widely available, allowing for earlier and more accurate detection of geographic atrophy. The adoption of these advanced technologies is likely to improve patient management and treatment outcomes. As healthcare providers increasingly utilize these tools, the demand for related services and products is expected to rise. Furthermore, the integration of artificial intelligence in diagnostic processes may streamline workflows and enhance the precision of diagnoses, potentially leading to a more robust geographic atrophy-ga market. This trend indicates a shift towards more proactive healthcare approaches in managing eye diseases. ### Growing Awareness and Education Initiatives Awareness campaigns and educational initiatives regarding geographic atrophy are gaining momentum in South America. Organizations and healthcare providers are increasingly focusing on informing the public about the risks and symptoms associated with this condition. Such efforts are likely to lead to higher rates of early diagnosis and treatment, which could positively impact the geographic atrophy-ga market. Increased awareness may also encourage individuals to seek regular eye examinations, further driving demand for diagnostic services. As more patients become informed about their options, the market may experience growth in both preventive measures and therapeutic interventions. This trend underscores the importance of education in enhancing patient outcomes and fostering a more informed patient population. ### Regulatory Support for Innovative Therapies Regulatory bodies in South America are increasingly supportive of innovative therapies for geographic atrophy, which may significantly influence the market landscape. Streamlined approval processes for new treatments can facilitate quicker access to cutting-edge therapies for patients. This regulatory environment appears to encourage pharmaceutical companies to invest in research and development, potentially leading to a wider array of treatment options. As new therapies enter the market, competition may intensify, driving down costs and improving accessibility for patients. The proactive stance of regulatory agencies in promoting innovation could thus play a pivotal role in shaping the future of the geographic atrophy-ga market, ensuring that patients have access to the latest advancements in care. ## Future Outlook The [Geographic Atrophy GA Market](https://www.marketresearchfuture.com/reports/geographic-atrophy-ga-market-10781) is projected to grow at a 7.28% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options. **New opportunities:** - Development of telemedicine platforms for remote patient monitoring - Investment in AI-driven diagnostic tools for early detection - Expansion of specialized clinics focusing on geographic atrophy treatment By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Age Group: Above 60 Years (Largest) vs. Above 75 Years (Fastest-Growing) In the market, the distribution of demographic segments indicates that individuals above 60 years constitute the largest share, reflecting the aging population trend prevalent in South America. This segment is critical as it encompasses a wide range of age-related pathologies, contributing significantly to the demand for geographic atrophy treatments. Conversely, the group above 75 years is emerging as the fastest-growing segment, driven by increased life expectancy and rising awareness about age-related eyesight degeneration. Innovations in treatment options and preventive care are fueling this growth, making it an area of strategic importance for market players looking to expand their reach in aging populations. Above 60 Years (Dominant) vs. Above 75 Years (Emerging) The segment comprising individuals above 60 years is currently the dominant force in the market, benefiting from a larger population base and established health care frameworks addressing age-related illnesses. This demographic is characterized by higher incidence rates of geographic atrophy, prompting significant investment in specialized treatments. In contrast, the above 75 years segment is recognized as the emerging market force, characterized by rapid growth due to a surge in this age cohort's number. This group often presents unique challenges, including increased medical complexities, necessitating tailored solutions and innovative interventions to effectively address their specific needs. ### By Diagnosis: Fundus Autofluorescence (FAF) (Largest) vs. Optical Coherence Tomography Angiography (OCT-A) (Fastest-Growing) In the market, Fundus Autofluorescence (FAF) holds the largest share among the diagnostic methods, driven by its ability to visualize retinal health effectively. This technique has gained considerable traction among clinicians for its non-invasive nature and informative imaging capabilities. On the other hand, Optical Coherence Tomography Angiography (OCT-A) is rapidly gaining market share due to its advanced imaging technology, providing detailed views of vascular structures in the eye, essential in monitoring geographic atrophy. The growth trends show that OCT-A is emerging as the fastest-growing diagnostic method, attracting investment and interest from research institutions and ophthalmic clinics. The increase in the aging population, coupled with the rise in diabetic and age-related macular degeneration cases, drives the demand for these technologies. Furthermore, ongoing advancements in imaging modalities and enhanced diagnosis accuracy are pivotal in expanding the adoption of these diagnostic tools in ophthalmology, making both FAF and OCT-A essential in clinical settings. Fundus Autofluorescence (Dominant) vs. Optical Coherence Tomography Angiography (Emerging) Fundus Autofluorescence (FAF) is the dominant diagnostic tool in the market, known for its efficacy in detecting retinal diseases through the visualization of lipofuscin accumulation. FAF's non-invasive approach has made it a preferred choice among ophthalmologists, allowing for thorough monitoring of retinal conditions. On the other hand, Optical Coherence Tomography Angiography (OCT-A) is an emerging technology that has gained popularity due to its ability to provide high-resolution images of ocular blood vessels without the need for dye injections. This technology supports better assessment of microvascular changes associated with geographic atrophy, thus driving its rapid adoption in clinical practice. Both methods complement each other, catering to the diagnostic needs of various retinal conditions. ### By Therapeutic Agents Clinical Phase: Late-Stage (Largest) vs. Phase II (Fastest-Growing) The market for therapeutic agents in the segment features a distinct distribution of clinical phases. The Late-Stage (Phase III) segment holds the largest market share, reflecting the significant investment and progression of several leading candidates in the development pipeline. Following behind, Phase II candidates exhibit notable activity with promising prospects, while Phase I and pre-clinical stages continue to contribute to the expanding therapeutic landscape, albeit at smaller proportions. Growth trends indicate a strong focus on advancing late-stage candidates, driven by increasing demand for effective treatments and investment in research and development. Furthermore, Phase II candidates are emerging as the fastest-growing segment, bolstered by favorable regulatory environments and heightened interest from pharmaceutical companies aiming to capitalize on the unmet needs in the geographic atrophy domain. These dynamics are likely to shape the strategic directions of stakeholders in this market. Late-Stage (Dominant) vs. Phase II (Emerging) In the segment comparison, Late-Stage (Phase III) therapeutic agents are currently dominant, characterized by robust clinical data supporting their efficacy and safety, which fosters confidence among clinicians and reimbursement bodies. These agents are positioned for near-term market entry and have significant backing from research institutions and biopharmaceutical companies. In contrast, Phase II agents are emerging with considerable potential; they showcase innovative mechanisms of action that could redefine treatment paradigms. This segment is witnessing rapid advancements and partnerships, attracting investments aimed at expediting their progression to late-stage trials, thus highlighting a dynamic shift towards new therapeutic options for managing geographic atrophy. ## Regional Market Share Analysis ### Brazil : Robust Growth and Demand Trends Brazil holds a commanding market share of 60% in the South American geographic atrophy (GA) market, valued at $600.0 million. Key growth drivers include an aging population, increasing awareness of eye health, and advancements in treatment options. Regulatory support from the Brazilian Health Regulatory Agency (ANVISA) has facilitated faster approvals for innovative therapies. Additionally, investments in healthcare infrastructure and telemedicine are enhancing access to treatments across urban and rural areas. ### Mexico : Growing Demand and Investment Opportunities Mexico accounts for 25% of the South American GA market, valued at $250.0 million. The growth is driven by rising healthcare expenditure and increasing prevalence of age-related eye diseases. Government initiatives aimed at enhancing healthcare infrastructure and public awareness campaigns are pivotal in driving demand. The regulatory environment is becoming more favorable, with streamlined processes for drug approvals, which is crucial for market expansion. ### Argentina : Focus on Healthcare Accessibility Argentina represents 20% of the South American GA market, valued at $200.0 million. The market is supported by a growing elderly population and increasing healthcare investments. However, economic instability poses challenges to consistent growth. Regulatory reforms are underway to improve drug accessibility, and local initiatives are focusing on enhancing patient education regarding GA. The demand for innovative therapies is rising, driven by both public and private healthcare sectors. ### Rest of South America : Varied Growth Across Regions The Rest of South America holds a 15% market share in the GA sector, valued at $150.0 million. This sub-region includes countries like Chile, Colombia, and Peru, each with distinct healthcare landscapes. Growth is driven by increasing awareness of GA and government initiatives to improve healthcare access. However, disparities in infrastructure and regulatory environments can hinder uniform growth. Local players are emerging, but major The geographic atrophy-ga market. ## Competitive Benchmarking The geographic atrophy-ga market in South America is characterized by a competitive landscape that is increasingly dynamic, driven by a combination of innovation, strategic partnerships, and regional expansion. Key players such as Novartis (CH), Regeneron Pharmaceuticals (US), and Roche (CH) are actively shaping the market through their focused operational strategies. Novartis (CH) emphasizes innovation in treatment modalities, particularly in gene therapy, which appears to be a focal point for addressing unmet medical needs. Regeneron Pharmaceuticals (US) is leveraging its robust pipeline of monoclonal antibodies, indicating a commitment to enhancing therapeutic options. Meanwhile, Roche (CH) is concentrating on expanding its diagnostic capabilities, which could potentially complement its therapeutic offerings, thereby creating a more integrated approach to patient care.The business tactics employed by these companies reflect a nuanced understanding of the market's structure, which is moderately fragmented yet increasingly competitive. Localizing manufacturing and optimizing supply chains are pivotal strategies that these companies are adopting to enhance operational efficiency and reduce costs. The collective influence of these key players suggests a trend towards consolidation, as companies seek to strengthen their market positions through strategic collaborations and acquisitions. In October Novartis (CH) announced a partnership with a local biotechnology firm to co-develop a novel treatment for geographic atrophy, which underscores its commitment to regional innovation. This collaboration not only enhances Novartis's product pipeline but also allows for localized insights into patient needs, potentially leading to more effective therapies. Similarly, in September 2025, Regeneron Pharmaceuticals (US) expanded its clinical trials in Brazil, focusing on a new monoclonal antibody that targets geographic atrophy. This move indicates a strategic effort to tap into the growing South American market, where the prevalence of age-related macular degeneration is rising. In August Roche (CH) launched a new diagnostic tool aimed at early detection of geographic atrophy, which could significantly alter treatment paradigms. This initiative reflects Roche's strategy to integrate diagnostics with therapeutics, thereby enhancing patient outcomes and positioning itself as a leader in comprehensive care solutions. Furthermore, in July 2025, Bayer (DE) announced an investment in digital health technologies to improve patient engagement and adherence to treatment regimens, suggesting a shift towards more patient-centric approaches in the market. As of November current competitive trends are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into healthcare solutions. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative innovation in addressing complex healthcare challenges. The competitive differentiation in this market is likely to evolve from traditional price-based competition to a focus on innovation, technology, and the reliability of supply chains. This shift may ultimately lead to enhanced patient outcomes and a more sustainable healthcare ecosystem in South America. ## Recent News & Developments In the South America Geographic Atrophy (GA) Market, recent developments indicate a notable increase in Research and Development investments focusing on therapeutic options and diagnostic tools targeted at retinal diseases. Companies such as Novartis and Bayer are making strides with innovative treatment approaches, while Alcon has expanded its product offering in the region to cater to the growing demand for ophthalmic solutions. In September 2023, EyeGate Pharmaceuticals announced an agreement with a South American distributor to enhance the availability of its GA treatments. Additionally, Kowa Company reported improved market penetration through partnerships with local health authorities in Brazil. Notably, in August 2023, Roche expanded its collaboration with Astellas Pharma, aiming to accelerate the development of new therapies for macular degeneration, thus strengthening their presence in the South American market. The valuation of the Geographic Atrophy market is expected to rise due to increasing patient awareness and government initiatives to support eye health, particularly in Argentina and Chile. Over the past couple of years, significant efforts to increase accessibility to treatments have been observed, contributing positively to the evolving landscape of the Geographic Atrophy market in South America. ## Report Scope | MARKET SIZE 2024 | 1200.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1287.36(USD Million) | | MARKET SIZE 2035 | 2600.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.28% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Alcon (CH), Apellis Pharmaceuticals (US), Genentech (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE) | | Segments Covered | Age Group, Diagnosis, Therapeutic Agents Clinical Phase | | Key Market Opportunities | Emerging therapies targeting geographic atrophy present significant growth potential in the evolving healthcare landscape. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the geographic atrophy market. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What was the overall market valuation for geographic atrophy in South America in 2024?** A: The overall market valuation for geographic atrophy in South America was $1200.0 Million in 2024. **Q: What is the projected market valuation for geographic atrophy in South America by 2035?** A: The projected market valuation for geographic atrophy in South America is $2600.0 Million by 2035. **Q: What is the expected CAGR for the South America geographic atrophy market during the forecast period 2025 - 2035?** A: The expected CAGR for the South America geographic atrophy market during the forecast period 2025 - 2035 is 7.28%. **Q: Which age group is projected to have the highest market valuation for geographic atrophy in South America?** A: The age group 'Above 60 Years' is projected to have a market valuation ranging from $720.0 Million to $1560.0 Million. **Q: What are the key diagnostic methods for geographic atrophy in South America and their market valuations?** A: Key diagnostic methods include Fundus Autofluorescence (FAF) with valuations of $300.0 Million to $650.0 Million and Optical Coherence Tomography Angiography (OCT-A) with valuations of $450.0 Million to $1000.0 Million. **Q: What is the market valuation for late-stage therapeutic agents in the South America geographic atrophy market?** A: The market valuation for late-stage (Phase III) therapeutic agents is projected to range from $600.0 Million to $1300.0 Million. **Q: Which companies are considered key players in the South America geographic atrophy market?** A: Key players in the market include Novartis, Regeneron Pharmaceuticals, Roche, Bayer, Alcon, Apellis Pharmaceuticals, Genentech, Santen Pharmaceutical, and Horizon Therapeutics. **Q: What is the market valuation for Phase II therapeutic agents in the South America geographic atrophy market?** A: The market valuation for Phase II therapeutic agents is projected to range from $300.0 Million to $650.0 Million. **Q: How does the market valuation for the 'Above 75 Years' age group compare to the 'Above 60 Years' age group?** A: The market valuation for the 'Above 75 Years' age group is projected to range from $480.0 Million to $1040.0 Million, which is lower than the 'Above 60 Years' age group. **Q: What is the projected market valuation for pre-clinical stage and discovery candidates in the South America geographic atrophy market?** A: The projected market valuation for pre-clinical stage and discovery candidates is expected to range from $100.0 Million to $250.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-geographic-atrophy-ga-market-51671*